.jpg)
Gene Therapy Biotech MeiraGTx Strikes Deal Bringing Generative AI to Pivotal Parkinson’s Trial
MeiraGTx’s gene therapy for Parkinson’s disease will enter Phase 3 testing under a new joint venture the biotech is forming with Hologen, a generative AI startup. The joint venture has up to $230 million in committed capital; MeiraGTx gets additional cash for its pipeline. The post Gene Therapy Biotech MeiraGTx Strikes Deal Bringing Generative AI to Pivotal Parkinson’s Trial appeared first on MedCity News.
MeiraGTx’s gene therapy for Parkinson’s disease will enter Phase 3 testing under a new joint venture the biotech is forming with Hologen, a generative AI startup. The joint venture has up to $230 million in committed capital; MeiraGTx gets additional cash for its pipeline.
The post Gene Therapy Biotech MeiraGTx Strikes Deal Bringing Generative AI to Pivotal Parkinson’s Trial appeared first on MedCity News.
